ebomi
Colour theme
Sign in
Insider · CIK 0001307729

Baker Brothers Life Sciences Capital (Gp), LLC

CIK 0001307729 Name as filed on the most recent filing

Filed as Baker Brothers Life Sciences Capital (Gp), LLC (174)· Baker Biotech Capital III (Gp), LLC (12)

647 transaction lines · from 186 filings · filed 2005-02-14 to 2012-03-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2012-03-14 P, Open-market purchase Tranzyme IncTZYM 2 lines 272,090, acquired Open Form 4 filing 0001144204-12-014965
2012-03-13 P, Open-market purchase Tranzyme IncTZYM 470,382, acquired Open Form 4 filing 0001144204-12-014965
2012-03-12 P, Open-market purchase Tranzyme IncTZYM 4 lines 2,341,269, acquired Open Form 4 filing 0001144204-12-014965
2012-03-08 P, Open-market purchase Genomic Health IncGHDX 592,489, acquired Open Form 4 filing 0001144204-12-014099
2012-03-07 P, Open-market purchase Genomic Health IncGHDX 659,464, acquired Open Form 4 filing 0001144204-12-014099
2012-03-05 P, Open-market purchase Genomic Health IncGHDX 2 lines 4,651,479, acquired Open Form 4 filing 0001144204-12-013006
2012-03-02 P, Open-market purchase Genomic Health IncGHDX 2,699,915, acquired Open Form 4 filing 0001144204-12-013006
2012-03-01 P, Open-market purchase Genomic Health IncGHDX 450,543, acquired Open Form 4 filing 0001144204-12-013006
2012-02-29 P, Open-market purchase Genomic Health IncGHDX 4,559,274, acquired Open Form 4 filing 0001144204-12-012152
2012-02-28 P, Open-market purchase Genomic Health IncGHDX 1,491,752, acquired Open Form 4 filing 0001144204-12-012152
2012-02-27 P, Open-market purchase Genomic Health IncGHDX 1,070,678, acquired Open Form 4 filing 0001144204-12-012152
2012-02-23 P, Open-market purchase Genomic Health IncGHDX 1,746,432, acquired Open Form 4 filing 0001144204-12-010672
2012-02-22 P, Open-market purchase Genomic Health IncGHDX 154,204, acquired Open Form 4 filing 0001144204-12-010672
2012-02-21 P, Open-market purchase Genomic Health IncGHDX 1,312,368, acquired Open Form 4 filing 0001144204-12-010672
2012-02-16 P, Open-market purchase Genomic Health IncGHDX 3 lines 5,499,497, acquired Open Form 4 filing 0001144204-12-009721
2012-02-15 P, Open-market purchase Genomic Health IncGHDX 927,680, acquired Open Form 4 filing 0001144204-12-009721
2012-02-14 P, Open-market purchase Genomic Health IncGHDX 1,586,898, acquired Open Form 4 filing 0001144204-12-009721
2012-02-10 P, Open-market purchase Genomic Health IncGHDX 3 lines 4,249,931, acquired Open Form 4 filing 0001144204-12-007402
2012-02-09 P, Open-market purchase Genomic Health IncGHDX 3 lines 1,473,628, acquired Open Form 4 filing 0001144204-12-007402
2012-02-08 P, Open-market purchase Genomic Health IncGHDX 3 lines 5,294,564, acquired Open Form 4 filing 0001144204-12-007402
2012-02-01 P, Open-market purchase Ardea Biosciences, Inc./DERDEA 14,906,076, acquired Open Form 4 filing 0001144204-12-005867
2012-01-26 P, Open-market purchase Pharmacyclics IncPCYC 2 lines 4,371,850, acquired Open Form 4 filing 0001144204-12-004225
2012-01-25 P, Open-market purchase Pharmacyclics IncPCYC 2 lines 2,326,615, acquired Open Form 4 filing 0001144204-12-004225
2012-01-24 P, Open-market purchase Pharmacyclics IncPCYC 2 lines 2,357,591, acquired Open Form 4 filing 0001144204-12-004225
2012-01-23 P, Open-market purchase Pharmacyclics IncPCYC 3 lines 2,737,009, acquired Open Form 4 filing 0001144204-12-003574
2012-01-20 P, Open-market purchase Pharmacyclics IncPCYC 2 lines 4,073,981, acquired Open Form 4 filing 0001144204-12-003574
2012-01-19 P, Open-market purchase Pharmacyclics IncPCYC 3 lines 559,459, acquired Open Form 4 filing 0001144204-12-003574
2012-01-13 P, Open-market purchase Incyte CorpINCY 1,692,732, acquired Open Form 4 filing 0001144204-12-002686
2012-01-13 P, Open-market purchase Incyte CorpINCY 1,209,822, acquired Open Form 4 filing 0001144204-12-002686

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Baker Brothers Life Sciences Capital (GP), LLC, insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001307729

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.